gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2023-33-6-7-15gastro-j-887Research ArticleОБЗОРЫREVIEWSВоспалительные заболевания кишечника у детей: современные достижения в диагностике и терапииInflammatory Bowel Diseases in Children: Modern Achievements in Diagnostics and Therapyhttps://orcid.org/0000-0001-7308-7280ХавкинА. И.KhavkinA. I.

Хавкин Анатолий Ильич — доктор медицинских наук, профессор, заведующий кафедрой гастроэнтерологии и диетологии им. А.В. Мазурина, руководитель Московского областного центра детской гастроэнтерологии и гепатологии; профессор кафедры педиатрии с курсом детских хирургических болезней Медицинского института 

115093, г. Москва, ул. Большая Серпуховская, 62

Anatoly I. Khavkin — Dr. Sci. (Med.), Professor, Head of the Department of Gastroenterology and Dietetics named after A.V. Mazurin, Head of the Moscow Regional Center of Pediatric Gastroenterology and Hepatology; Professor of the Department of Pediatrics with a Course in Pediatric Surgical Diseases, Medical Institute

115093, Moscow, Bolshaya Serpukhovskaya str., 62

khavkin@nikid.ruhttps://orcid.org/0000-0002-4733-3262НалетовА. В.NalyotovA. V.

Налетов Андрей Васильевич — доктор медицинских наук, профессор, заведующий кафедрой педиатрии № 2 

283003, г. Донецк, просп. Ильича, 16

Andrew V. Nalyotov — Dr. Sci. (Med.), Professor, Head of the Department of Pediatrics No. 2

283003, Donetsk, Illicha avе., 16

https://orcid.org/0009-0007-7203-3775МарченкоН. А.MarchenkoN. A.

Марченко Наталия Александровна — ассистент кафедры педиатрии № 2

283003, г. Донецк, просп. Ильича, 16

Nataliya A. Marchenko — Teaching Assistant of the Department of Pediatrics No. 2

283003, Donetsk, Illicha avе., 16

ГБУЗ МО «Научно-исследовательский клинический институт детства» Министерства здравоохранения Московской области; ФГАОУ ВО «Белгородский государственный национальный исследовательский университет»РоссияResearch Clinical Institute of Childhood of the Moscow Region; Belgorod National Research UniversityRussian FederationФГБОУ ВО «Донецкий государственный медицинский университет им. М. Горького» Министерства здравоохранения Российской ФедерацииРоссияDonetsk State Medical University name after M. GorkyRussian Federation202302122023336715Copyright © Хавкин А.И., Налетов А.В., Марченко Н.А., 20242024Хавкин А.И., Налетов А.В., Марченко Н.А.Khavkin A.I., Nalyotov A.V., Marchenko N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/887Цель обзора литературы

Цель обзора литературы: осветить современные тенденции в диагностике и лечении воспалительных заболеваний кишечника у детей.

Основные положения

Основные положения. Заболеваемость воспалительными заболеваниями кишечника среди детей значительно выросла за последние три десятилетия, причем эти болезни часто характеризуются тяжелым течением. В то же время совершенствуются стратегии диагностики и лечения пациентов с этими заболеваниями желудочно-кишечного тракта: в качестве методов диагностики применяют эндоскопию высокого разрешения и видеокапсульную эндоскопию, определение фекального кальпротектина, внедряется биологическая терапия (инфликсимаб, адалимумаб, ведолизумаб и устекинумаб) и лекарственный мониторинг. Особое внимание уделяется роли диетических рекомендаций.

Заключение

Заключение. В настоящее время наблюдается значительный прогресс в диагностике и лечение воспалительных заболеваний кишечника у детей. 

Aim

Aim: to highlight current trends in the diagnosis and treatment of inflammatory bowel diseases in children.

Key points

Key points. The incidence of inflammatory bowel disease among children has increased significantly over the past three decades. Moreover, these diseases are often characterized by a severe course. At the same time, strategies for diagnosing and treating these patients are being improved: doctors began using high-definition endoscopy and video capsule endoscopy, the determination of fecal calprotectin, biological therapy (infliximab, adalimumab, vedolizumab, and ustekinumab) and drug monitoring. Particular attention is paid to the role of dietary recommendations.

Conclusion

Conclusion. Currently, there has been significant progress in the diagnosis and treatment of inflammatory bowel diseases in children.

воспалительные заболевания кишечникаязвенный колитболезнь Кронафекальный кальпротектининфликсимабадалимумабведолизумабустекинумабinflammatory bowel diseasesulcerative colitisCrohn's diseasefecal calprotectininfliximabadalimumabvedolizumabustekinumabReferencesGraham D. B., Xavier R. J. Pathway paradigms revealed from the genetics of inflammatory bowel disease. Nature. 2020; 578: 527–39. DOI: 10.1038/s41586-020-2025-2Graham D. B., Xavier R. J. Pathway paradigms revealed from the genetics of inflammatory bowel disease. Nature. 2020; 578: 527–39. DOI: 10.1038/s41586-020-2025-2Kuenzig M. E., Fung S. G., Marderfeld L. et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. Gastroenterology 2022; 162: 1147–59. DOI: 10.1053/j.gastro.2021.12.282Kuenzig M. E., Fung S. G., Marderfeld L. et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. Gastroenterology 2022; 162: 1147–59. DOI: 10.1053/j.gastro.2021.12.282Ashton J. J., Barakat F. M., Barnes C. et al. Incidence and prevalence of paediatric inflammatory bowel disease continues to increase in the south of England. J Pediatr Gastroenterol Nutr. 2022; 75: e20–4. DOI: 10.1097/MPG.0000000000003511Ashton J. J., Barakat F. M., Barnes C. et al. Incidence and prevalence of paediatric inflammatory bowel disease continues to increase in the south of England. J Pediatr Gastroenterol Nutr. 2022; 75: e20–4. DOI: 10.1097/MPG.0000000000003511Henderson P., Hansen R., Cameron F. L. et al. Rising incidence of pediatric inflammatory bowel disease in Scotland. Inflamm Bowel Dis. 2012; 18: 999–1005. DOI: 10.1002/ibd.21797Henderson P., Hansen R., Cameron F. L. et al. Rising incidence of pediatric inflammatory bowel disease in Scotland. Inflamm Bowel Dis. 2012; 18: 999–1005. DOI: 10.1002/ibd.21797Jones G-R., Lyons M., Plevris N. et al. IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology. Gut. 2019; 68: 1953–60. DOI: 10.1136/gutjnl-2019-318936Jones G-R., Lyons M., Plevris N. et al. IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology. Gut. 2019; 68: 1953–60. DOI: 10.1136/gutjnl-2019-318936Ashton J. J., Mossotto E., Ennis S. et al. Personalising medicine in inflammatory bowel disease-current and future perspectives. Transl Pediatr. 2019; 8: 56–69. DOI: 10.21037/tp.2018.12.03Ashton J. J., Mossotto E., Ennis S. et al. Personalising medicine in inflammatory bowel disease-current and future perspectives. Transl Pediatr. 2019; 8: 56–69. DOI: 10.21037/tp.2018.12.03Яблокова Е. А., Джабарова А. К., Лохматов М. М., Горелов А. В., Крутихина С. Б., Ерохина М. И., Чибрина Е. В., Римская А. М., Хавкин А. И. Внекишечные проявления воспалительных заболеваний кишечника у детей. Экспериментальная и клиническая гастроэнтерология. 2023; 209 (1): 165–177. DOI: 10.31146/1682-8658-ecg-209-1-165-177Yablokova E. A., Dzhabarova A. K., Lokhmatov M. M., Gorelov A. V., Krutikhina S. B., Erokhina M. I., Chibrina E. V., Rimskaya A. M., Khavkin A. I. Extraintestinal manifestations in infl ammatory bowel diseases in children, a modern view of the problem. Experimental and Clinical Gastroenterology. 2023; 209 (1): 165–177. (In Russ.) DOI: 10.31146/1682-8658-ecg-209-1-165-177Ricciuto A., Fish J. R., Tomalty D. E. et al. Diagnostic delay in Canadian children with inflammatory bowel disease is more common in Crohn’s disease and associated with decreased height. Arch Dis Child. 2018; 103: 319–26. DOI: 10.1136/archdischild-2017-313060Ricciuto A., Fish J. R., Tomalty D. E. et al. Diagnostic delay in Canadian children with inflammatory bowel disease is more common in Crohn’s disease and associated with decreased height. Arch Dis Child. 2018; 103: 319–26. DOI: 10.1136/archdischild-2017-313060Будкина Т. Н., Лохматов М. М., Тупыленко А. В., Олдаковский В. И., Королёв Г. А., Яблокова Е. А., Хавкин А. И. Клинические рекомендации по эндоскопической диагностике и мониторингу болезни Крона у детей (проект). Экспериментальная и клиническая гастроэнтерология. 2023; 209 (1): 87–97. DOI: 10.31146/1682-8658-ecg-209-1-87-97Budkina T. N., Lokhmatov M. M., Tupylenko A. V., Oldakovsky V. I., Korolev G. A., Yablokova E. A., Khavkin A. I. Clinical guidelines for endoscopic diagnosis and monitoring of Crohn’s disease in children (Draft). Experimental and Clinical Gastroenterology. 2023;209(1): 87–97. (In Russ.) DOI: 10.31146/1682-8658-ecg-209-1-87-97Ashton J. J., Borca F., Mossotto E. et al. Analysis and hierarchical clustering of blood results before diagnosis in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2020; 26: 469–75. DOI: 10.1093/ibd/izy369Ashton J. J., Borca F., Mossotto E. et al. Analysis and hierarchical clustering of blood results before diagnosis in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2020; 26: 469–75. DOI: 10.1093/ibd/izy369Saha A., Tighe M. P., Batra A. How to use faecal calprotectin in management of paediatric inflammatory bowel disease. Arch Dis Child Educ Pract Ed. 2016; 101: 124–8. DOI: 10.1136/archdischild-2014-307941Saha A., Tighe M. P., Batra A. How to use faecal calprotectin in management of paediatric inflammatory bowel disease. Arch Dis Child Educ Pract Ed. 2016; 101: 124–8. DOI: 10.1136/archdischild-2014-307941Ситкин С .И., Авалуева Е. Б., Бакулин И. Г., Скалинская М. И., Воробьёв С. Л., Павлова Е. Ю., Хавкин А. И. Роль бактериальных, грибковых и вирусных инфекций в патогенезе воспалительных заболеваний кишечника. Инфекционные болезни. 2023; 21(2): 64–81. DOI: 10.20953/1729-9225-2023-2-64-81Sitkin S. I., Avalueva E. B., Bakulin I. G., Skalinskaya M. I., Vorobyev S. L., Pavlova E. Yu., Khavkin A. I. The role of bacterial, fungal, and viral infections in the pathogenesis of inflammatory bowel disease. Infekc. bolezni (Infectious Diseases). 2023; 21 (2): 64–81. (In Russian). DOI: 10.20953/ 1729-9225-2023-2-64-81Stawczyk-Eder K., Eder P., Lykowska-Szuber L. et al. Is faecal calprotectin equally useful in all Crohn’s disease locations? A prospective, comparative study. Arch Med Sci 2015; 11: 353–61. DOI: 10.5114/aoms.2014.43672Stawczyk-Eder K., Eder P., Lykowska-Szuber L. et al. Is faecal calprotectin equally useful in all Crohn’s disease locations? A prospective, comparative study. Arch Med Sci 2015; 11: 353–61. DOI: 10.5114/aoms.2014.43672Levine A., Koletzko S., Turner D. et al. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014; 58: 795–806. 10.1097/MPG.0000000000000239Levine A., Koletzko S., Turner D. et al. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014; 58: 795–806. 10.1097/MPG.0000000000000239Radford S. J., Clarke C., Shinkins B. et al. Clinical utility of small bowel ultrasound assessment of Crohn’s disease in adults: a systematic scoping review. Frontline Gastroenterol. 2022; 13: 280–6. DOI: 10.1136/flgastro-2021-101897Radford S. J., Clarke C., Shinkins B. et al. Clinical utility of small bowel ultrasound assessment of Crohn’s disease in adults: a systematic scoping review. Frontline Gastroenterol. 2022; 13: 280–6. DOI: 10.1136/flgastro-2021-101897Cohen S.A., Oliva S. Capsule endoscopy in children. Front Pediatr. 2021; 9: 664722. DOI: 10.3389/fped.2021.664722Cohen S.A., Oliva S. Capsule endoscopy in children. Front Pediatr. 2021; 9: 664722. DOI: 10.3389/fped.2021.664722Uhlig H. H., Schwerd T., Koletzko S. et al. The diagnostic approach to Monogenic very early onset inflammatory bowel disease. Gastroenterology. 2014; 147: 990–1007. DOI: 10.1053/j.gastro.2014.07.023Uhlig H. H., Schwerd T., Koletzko S. et al. The diagnostic approach to Monogenic very early onset inflammatory bowel disease. Gastroenterology. 2014; 147: 990–1007. DOI: 10.1053/j.gastro.2014.07.023Bolton C., Smillie C. S., Pandey S. et al. An integrated taxonomy for monogenic inflammatory bowel disease. Gastroenterology. 2022; 162: 859–76. DOI: 10.1053/j.gastro.2021.11.014Bolton C., Smillie C. S., Pandey S. et al. An integrated taxonomy for monogenic inflammatory bowel disease. Gastroenterology. 2022; 162: 859–76. DOI: 10.1053/j.gastro.2021.11.014Kammermeier J., Lamb C. A., Jones K. D. J. et al. Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults: consensus guideline on behalf of the British society of gastroenterology and British society of paediatric gastroenterology, hepatology and nutrition. Lancet Gastroenterol Hepatol. 2023; 8: 271–86. DOI: 10.1016/S2468-1253(22)00337-5Kammermeier J., Lamb C. A., Jones K. D. J. et al. Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults: consensus guideline on behalf of the British society of gastroenterology and British society of paediatric gastroenterology, hepatology and nutrition. Lancet Gastroenterol Hepatol. 2023; 8: 271–86. DOI: 10.1016/S2468-1253(22)00337-5van Rheenen P. F., Aloi M., Assa A. et al. The medical management of paediatric Crohn’s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis. 2020: jjaa161. DOI: 10.1093/ecco-jcc/jjaa161van Rheenen P. F., Aloi M., Assa A. et al. The medical management of paediatric Crohn’s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis. 2020: jjaa161. DOI: 10.1093/ecco-jcc/jjaa161Quality standards for specialist Paediatric Gastroenterology, Hepatology and nutrition [RCPCH]. Available: https://www.rcpch.ac.uk/resources/quality-standards-specialistpaediatric-gastroenterology-hepatology-nutrition.Quality standards for specialist Paediatric Gastroenterology, Hepatology and nutrition [RCPCH]. Available: https://www.rcpch.ac.uk/resources/quality-standards-specialistpaediatric-gastroenterology-hepatology-nutrition.Smith P. J., Critchley L., Storey D. et al. Efficacy and safety of elective switching from intravenous to subcutaneous Infliximab [CT-P13]: a multicentre cohort study. J Crohns Colitis. 2022; 16: 1436–46. DOI: 10.1093/ecco-jcc/jjac053Smith P. J., Critchley L., Storey D. et al. Efficacy and safety of elective switching from intravenous to subcutaneous Infliximab [CT-P13]: a multicentre cohort study. J Crohns Colitis. 2022; 16: 1436–46. DOI: 10.1093/ecco-jcc/jjac053Ashton J. J., Gavin J., Beattie R. M. Exclusive enteral nutrition in Crohn’s disease: evidence and practicalities. Clin Nutr. 2019; 38: 80–9. DOI: 10.1016/j.clnu.2018.01.020Ashton J. J., Gavin J., Beattie R. M. Exclusive enteral nutrition in Crohn’s disease: evidence and practicalities. Clin Nutr. 2019; 38: 80–9. DOI: 10.1016/j.clnu.2018.01.020Gkikas K., Gerasimidis K., Milling S. et al. Dietary strategies for maintenance of clinical remission in inflammatory bowel diseases: are we there yet. Nutrients. 2020; 12: 2018. DOI: 10.3390/nu12072018Gkikas K., Gerasimidis K., Milling S. et al. Dietary strategies for maintenance of clinical remission in inflammatory bowel diseases: are we there yet. Nutrients. 2020; 12: 2018. DOI: 10.3390/nu12072018Sigall-Boneh R., Levine A., Lomer M. et al. Research gaps in diet and nutrition in inflammatory bowel disease. A topical review by D-ECCO working group [Dietitians of ECCO]. J Crohns Colitis. 2017; 11: 1407–19. DOI: 10.1093/ecco-jcc/jjx109Sigall-Boneh R., Levine A., Lomer M. et al. Research gaps in diet and nutrition in inflammatory bowel disease. A topical review by D-ECCO working group [Dietitians of ECCO]. J Crohns Colitis. 2017; 11: 1407–19. DOI: 10.1093/ecco-jcc/jjx109Marino L. V., Ashton J. J., Beattie R. M. The impact of national Lockdown on nutritional status of children with inflammatory bowel disease. J Hum Nutr Diet. 2021; 34: 656–9. DOI: 10.1111/jhn.12862Marino L. V., Ashton J. J., Beattie R. M. The impact of national Lockdown on nutritional status of children with inflammatory bowel disease. J Hum Nutr Diet. 2021; 34: 656–9. DOI: 10.1111/jhn.12862Хавкин А. И., Завьялова А. Н., Новикова В. П., Яблокова Е. А., Чуракова И. Ю., Яковлева М. Н., Ерохина М. И., Чибрина Е. В., Лисовская Е. О. Особенности физического развития и нутритивного статуса детей с болезнью Крона. Вопросы практической педиатрии. 2023; 18 (1): 72–79. DOI: 10.20953/1817-7646-2023-1-72-79Khavkin A. I., Zavyalova A. N., Novikova V. P., Yablokova E. A., Churakovа I. Yu., Yakovleva M. N., Erokhina M. I., Chibrina E. V., Lisovskaya E. O. Features of physical development and nutritional status of children with Crohn disease. Vopr. prakt. pediatr. (Clinical Practice in Pediatrics). 2023; 18 (1): 72–79. (In Russian). DOI: 10.20953/1817-7646-2023-1-72-79Nguyen N.H., Solitano V., Vuyyuru S.K. et al. Proactive therapeutic drug monitoring versus conventional management for inflammatory bowel diseases: a systematic review and meta-analysis. Gastroenterology 2022; 163: 937–49. DOI: 10.1053/j.gastro.2022.06.052Nguyen N.H., Solitano V., Vuyyuru S.K. et al. Proactive therapeutic drug monitoring versus conventional management for inflammatory bowel diseases: a systematic review and meta-analysis. Gastroenterology 2022; 163: 937–49. DOI: 10.1053/j.gastro.2022.06.052Jongsma M.M.E., Aardoom M.A., Cozijnsen M.A. et al. First-line treatment with Infliximab versus conventional treatment in children with newly diagnosed moderate-tosevere Crohn’s disease: an open-label Multicentre randomised controlled trial. Gut. 2022; 71: 34–42. DOI: 10.1136/gutjnl-2020-322339Jongsma M.M.E., Aardoom M.A., Cozijnsen M.A. et al. First-line treatment with Infliximab versus conventional treatment in children with newly diagnosed moderate-tosevere Crohn’s disease: an open-label Multicentre randomised controlled trial. Gut. 2022; 71: 34–42. DOI: 10.1136/gutjnl-2020-322339Tsui J.J., Huynh H.Q. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn’s disease Ann Gastroenterol. 2018; 31: 413–24. DOI: 10.20524/aog.2018.0253Tsui J.J., Huynh H.Q. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn’s disease Ann Gastroenterol. 2018; 31: 413–24. DOI: 10.20524/aog.2018.0253Boyapati R.K., Ho G.T., Satsangi J. Top-down in the long term in Crohn’s disease. J Crohns Colitis. 2018; 12: 513–4. DOI: 10.1093/ecco-jcc/jjy027Boyapati R.K., Ho G.T., Satsangi J. Top-down in the long term in Crohn’s disease. J Crohns Colitis. 2018; 12: 513–4. DOI: 10.1093/ecco-jcc/jjy027Papamichael K., Afif W., Drobne D. et al. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 2022; 7: 171–85. DOI: 10.1016/S2468-1253(21)00223-5Papamichael K., Afif W., Drobne D. et al. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 2022; 7: 171–85. DOI: 10.1016/S2468-1253(21)00223-5Hendy P., Hart A., Irving P. Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide. Frontline Gastroenterol. 2016; 7: 122–8. DOI: 10.1136/flgastro-2014-100527Hendy P., Hart A., Irving P. Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide. Frontline Gastroenterol. 2016; 7: 122–8. DOI: 10.1136/flgastro-2014-100527Sazonovs A., Kennedy N.A., Moutsianas L. et al. HLA-Dqa1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease. Gastroenterology. 2020; 158: 189–99. DOI: 10.1053/j.gastro.2019.09.041Sazonovs A., Kennedy N.A., Moutsianas L. et al. HLA-Dqa1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease. Gastroenterology. 2020; 158: 189–99. DOI: 10.1053/j.gastro.2019.09.041Mahmoud R., Schultheiss H-P., Louwers J. et al. Immunomodulator withdrawal from anti-TNF therapy is not associated with loss of response in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2022; 20: 2577–87. DOI: 10.1016/j.cgh.2022.01.019Mahmoud R., Schultheiss H-P., Louwers J. et al. Immunomodulator withdrawal from anti-TNF therapy is not associated with loss of response in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2022; 20: 2577–87. DOI: 10.1016/j.cgh.2022.01.019Chavannes M., Martinez-Vinson C., Hart L. et al. Management of paediatric patients with medically refractory Crohn’s disease using ustekinumab: a multi-centred cohort study. J Crohns Colitis. 2019; 13: 578–84. DOI: 10.1093/ecco-jcc/jjy206Chavannes M., Martinez-Vinson C., Hart L. et al. Management of paediatric patients with medically refractory Crohn’s disease using ustekinumab: a multi-centred cohort study. J Crohns Colitis. 2019; 13: 578–84. DOI: 10.1093/ecco-jcc/jjy206Ledder O., Assa A., Levine A. et al. Vedolizumab in paediatric inflammatory bowel disease: a retrospective multi-centre experience from the paediatric IBD Porto group of ESPGHAN. J Crohns Colitis. 2017; 11: 1230–7. DOI: 10.1093/ecco-jcc/jjx082Ledder O., Assa A., Levine A. et al. Vedolizumab in paediatric inflammatory bowel disease: a retrospective multi-centre experience from the paediatric IBD Porto group of ESPGHAN. J Crohns Colitis. 2017; 11: 1230–7. DOI: 10.1093/ecco-jcc/jjx082Olivera P., Danese S., Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017; 66: 199‒209. DOI: 10.1136/gutjnl-2016-312912Olivera P., Danese S., Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017; 66: 199‒209. DOI: 10.1136/gutjnl-2016-312912Toskas A., Akbar A. IBD Therapeutics: what is in the pipeline. Frontline Gastroenterol 2022; 13: e35–43. DOI: 10.1136/flgastro-2022-102130Toskas A., Akbar A. IBD Therapeutics: what is in the pipeline. Frontline Gastroenterol 2022; 13: e35–43. DOI: 10.1136/flgastro-2022-102130Шрайнер Е. В., Хавкин А. И., Новикова М. С., Тикунов А. Ю., Чечушков А. В., Харахорин Р. А., Тикунова Н. В. Современные стратегии и перспективы лечения язвенного колита. Экспериментальная и клиническая гастроэнтерология. 2023;209(1): 149–157. DOI: 10.31146/1682-8658-ecg-209-1-149-157Shrayner E. V., Khavkin A. I., Novikova M. S., Tikunov A. Yu., Chechushkov A. V., Kharakhorin R. A., Tikunova N. V. Modern strategies and prospects for the treatment of ulcerative colitis. Experimental and Clinical Gastroenterology. 2023; 209 (1): 149–157. (In Russ.) DOI: 10.31146/1682-8658-ecg-209-1-149-157

The authors declare that there are no conflicts of interest present.